REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo before transplant may stop blood cancer return
Disease control Recruiting nowThis study tests a new approach for adults with aggressive blood cancers (like AML) that are hard to treat. Patients get a stronger chemotherapy mix (decitabine plus FLAG-Ida) and total body radiation, followed by a donor stem cell transplant. The goal is to kill cancer cells and…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
New combo therapy aims to beat relapsed blood cancers
Disease control Recruiting nowThis study is for adults with certain blood cancers (like acute myeloid leukemia) that have come back or not responded to standard treatment. Participants receive a strong chemotherapy combination (CLAG-M or FLAG-Ida) followed immediately by a stem cell transplant from a donor. T…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemias
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk leukemias or related blood cancers. The antibody targets cancer cells and delivers radiation to help kill them while sparing healthy cells. The goal is to f…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New combo aims to boost leukemia treatment
Disease control Recruiting nowThis study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will be e…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Radioactive antibody blasts cancer before stem cell rescue in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC